NYSE:CCChemours Stock Price, Forecast & News

Chemours' stock was trading at $10.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CC shares have increased by 96.7% and is now trading at $20.97.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 8 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Chemours.

Chemours is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Chemours.

Chemours Co (NYSE:CC) released its quarterly earnings data on Thursday, July, 30th. The specialty chemicals company reported $0.18 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.09 by $0.09. The specialty chemicals company earned $1.09 billion during the quarter, compared to analysts' expectations of $1.08 billion. Chemours had a positive return on equity of 47.31% and a negative net margin of 2.28%.
View Chemours' earnings history.

Chemours announced a quarterly dividend on Wednesday, July 29th. Stockholders of record on Monday, August 17th will be given a dividend of $0.25 per share on Tuesday, September 15th. This represents a $1.00 annualized dividend and a yield of 4.77%. The ex-dividend date is Friday, August 14th.
View Chemours' dividend history.

11 brokerages have issued twelve-month target prices for Chemours' shares. Their forecasts range from $11.00 to $22.00. On average, they anticipate Chemours' share price to reach $16.60 in the next year. This suggests that the stock has a possible downside of 20.8%.
View analysts' price targets for Chemours.

Media stories about CC stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chemours earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Chemours.

Some companies that are related to Chemours include ASAHI KASEI COR/ADR (AHKSY), Johnson Matthey (JMPLY), Ashland Global (ASH), Huntsman (HUN), KURARAY CO LTD/ADR (KURRY), Balchem (BCPC), Univar (UNVR), SHOWA DENKO KK/ADR (SHWDY), W. R. Grace & Co (GRA), Ingevity (NGVT), Innospec (IOSP), GCP Applied Technologies (GCP), Olin (OLN), PQ Group (PQG) and Livent (LTHM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), AT&T (T), NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), Cisco Systems (CSCO), AbbVie (ABBV), Energy Transfer LP Unit (ET), Intel (INTC) and CVS Health (CVS).

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.24%), Vanguard Group Inc. (9.60%), Sessa Capital IM L.P. (6.59%), LSV Asset Management (2.51%), Bank of New York Mellon Corp (1.90%) and Goldman Sachs Group Inc. (0.58%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Edwin C Sparks, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher.
View institutional ownership trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Partners Capital Investment Group LLP, State of Wisconsin Investment Board, First Trust Advisors LP, DNB Asset Management AS, Holocene Advisors LP, and Prudential Financial Inc.. Company insiders that have sold Chemours company stock in the last year include Edwin C Sparks, and Mark P Vergnano.
View insider buying and selling activity for Chemours.

CC stock was acquired by a variety of institutional investors in the last quarter, including Sessa Capital IM L.P., Point72 Asset Management L.P., Portolan Capital Management LLC, Brightline Capital Management LLC, Vanguard Group Inc., Advisors Asset Management Inc., Federated Hermes Inc., and Bank of New York Mellon Corp. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown, and Susan M Kelliher.
View insider buying and selling activity for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CC stock can currently be purchased for approximately $20.97.

Chemours has a market capitalization of $3.44 billion and generates $5.53 billion in revenue each year. The specialty chemicals company earns $-52,000,000.00 in net income (profit) each year or $2.51 on an earnings per share basis. Chemours employs 7,000 workers across the globe.

The official website for Chemours is www.chemours.com.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]